Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

American Public Education

Landbridge Co LLC

McKesson stock is nearing a buy point. Its relative strength line reached a new high as did two others that have nearly doubled in price.

These 3 Stocks Trade Near Buy Points, Get Bullish Designation

Cigna

GE HealthCare Technologies Inc

HCA Healthcare

Intuitive Surgical

Eli Lilly

Thermo Fisher Scientific

There are a whole host of reasons to invest in healthcare stocks over the long term. The United States has an aging population.

Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth

In the latest trading session, McKesson (MCK) closed at $600.16, marking a +0.74% move from the previous day.

McKesson (MCK) Increases Yet Falls Behind Market: What Investors Need to Know

McKesson (MCK) closed at $585.74 in the latest trading session, marking a +0.47% move from the prior day.

McKesson (MCK) Increases Despite Market Slip: Here's What You Need to Know

McKesson's (MCK) shares have risen 1.5% year to date on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.

McKesson (MCK) Gains 26% Year to Date: What's Backing the Rally?

McKesson's (MCK) robust Biologics business raises optimism about the stock.

3 Reasons Why You Should Hold McKesson (MCK) Stock for Now

In the latest trading session, McKesson (MCK) closed at $575.23, marking a -1.98% move from the previous day.

McKesson (MCK) Declines More Than Market: Some Information for Investors

IRVING, Texas--(BUSINESS WIRE)--McKesson released its FY24 Impact Report, showcasing the company's ongoing commitment to its purpose of Advancing Health Outcomes for All®.

McKesson Releases Fiscal Year 2024 Impact Report

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2025 financial results after market close on Wednesday, August 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide prese.

McKesson Corporation Announces First Quarter Fiscal 2025 Earnings Release Date

IRVING, Texas--(BUSINESS WIRE)--McKesson ideaShare hosted nearly 2,700 attendees including independent pharmacy owners and their staff in New Orleans.

McKesson ideaShare Ignites and Inspires Independent Community Pharmacies

NEW ORLEANS--(BUSINESS WIRE)--Outcomes, a leader in integrated pharmacy workflow and patient engagement solutions, announced that it will feature a new prescription counting solution, Pill Count, at McKesson ideaShare. By leveraging AI and machine learning, Pill Count™ makes counting pills easier and more accurate. This is the latest solution for Outcomes, a company that offers a full suite of patient engagement, clinical and pharmacy workflow solutions across the nation's largest community net.

Outcomes® Showcased at McKesson ideaShare 2024

Elevance Health Inc

The healthcare sector is often considered a defensive play, with healthcare stocks to buy offering stability and growth potential even during economic downturns. The sector's strength is driven by an aging global population, rising healthcare expenditures, and advancements in medical technology.

The 3 Healthiest Healthcare Stocks to Buy for a Huge Dose of Profits

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

McKesson (MCK) Reaches 52-Week High: What's Aiding the Stock?

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.

McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug

McKesson (MCK) closed at $589.95 in the latest trading session, marking a -0.19% move from the prior day.

McKesson (MCK) Sees a More Significant Dip Than Broader Market: Some Facts to Know

The latest trading day saw McKesson (MCK) settling at $591.07, representing a +1.07% change from its previous close.

McKesson (MCK) Laps the Stock Market: Here's Why

McKesson's (MCK) shares have risen year to date on the back of strong fundamentals. Rising volumes of prescription and specialty drugs boost the top line.

McKesson (MCK) Gains 26% YTD: What's Driving the Rally?

Costco

MercadoLibre

MicroStrategy Incorporated

NVIDIA

Palantir Technologies

Synopsys

Traders and other investors looking to take short positions in trending stocks with momentum on their side should consider this list. It covers seven equities that have maintained positive trajectories over the past month and in many cases, the entirety of this year and beyond.

7 Trending Stocks With Momentum on Their Side

Booking Hlds

There is no end in sight to the stock market's latest bull run. These S&P 500 stocks keep rising, hitting new all-time highs.

3 No-Nonsense S&P 500 Stocks to Buy and Hold Forever

McKesson Corporation (MCK) is poised to grow due to an aging population and expanding Type 2 diabetes treatments.

McKesson is a Growing Giant

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Here's Why You Should Hold McKesson (MCK) in Your Portfolio Now

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that the McKesson board of directors has elected Dr. Deborah Dunsire as a director and member of the Compensation and Talent Committee and Finance Committee, effective June 3, 2024. “We're pleased to welcome Deborah to the McKesson board,” said Donald Knauss, McKesson's independent board chair. “She is a highly respected healthcare industry leader with a proven track record of leading large, complex organizations a.

McKesson's Board of Directors Elects Deborah Dunsire as New Director

Northrop Grumman

T-Mobile US

In retirement, stability and downside protection are the main investment objectives. You need retirement-proof stocks that guarantee stable growth with minimal volatility to succeed.

News for McKesson Stock (MCK)